In the third quarter of 2010, biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million, a 29% jump from the previous quarter and a 50% increase from the third quarter of 2009. ( See Exhibit 1.) Biopharma companies did well in Q3, bringing in $446 million, or 30% more than the previous quarter. Not so for in vitro diagnostics start-ups, which raised just $99 million, 39% less than they did in Q2. Device companies were the most successful at generating more funds compared with Q2 – with a 130% hike. (This spike was mostly due to Devicor Medical Products Inc.'s equity financing, which accounted for 66% of Q3's device total.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?